Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit

Current Cardiology Reports

Volumn 3, Issue 5, 2001, Pages 424-432

  Sprecher, Dennis L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; PROGNOSIS; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; PROGNOSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 0035458597     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0060-7     Document Type: Article

References (63)

1. Albrink M, Man E: Serum triglycerides in coronary artery disease. Arch Int Med 1959, 103:4-8.
2. Castelli WP, Garrison RJ, Wilson PW, et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986, 256:2835-2838.
3. Gordon DJ, Knoke J, Probstfield JL, et al.: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986, 74:1217-1225.
4. Assmann G, Cullen P, Schulte H: The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 1998, 19:A2-A11.
5. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease: an 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997, 17:1114-1120.
6. Gordon T, Castelli WP, Hjortland MC, et al.: High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977, 62:707-714.
7. Sprecher DL, Pearce GL, Cosgrove DM, et al.: Relation of serum triglyceride levels to survival after coronary artery bypass grafting. Am J Cardiol 2000, 86:285-288.
8. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of populationbased prospective studies. J Cardiovasc Risk 1996, 3:213-219.
9. Mosca L, Manson JE, Sutherland SE, et al.: Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1997, 96:2468-2482.
10. Austin MA: Plasma triglyceride as a risk factor for cardiovascular disease. Canadian Journal of Cardiology 1998, 14:14B-17B.
11. Stern MP, Mitchell BD, Haffner SM, Hazuda HP: Does glycemic control of type II diabetes suffice to control diabetic dyslipidemia? A community perspective. Diabetes Care 1992, 15:638-644.
12. Ginsberg HN: Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996, 45:S27-S30.
13. Criqui MH, Heiss G, Cohn R, et al.: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993, 328:1220-1225.
14. Sprecher D, Pearce G, Park E, et al.: Preoperative triglycerides predict post-coronary artery bypass graft survival in diabetic patients. Diabetes Care 2000, 23:1648-1653.
15. Fontbonne AM, Eschwege EM: Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991, 14:461-469.
16. Lehto S, Ronnemaa T, Haffner SM, et al.: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997, 46:1354-1359.
17. Reaven GM: Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
18. Havel R, Eder H, Bragdon J: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955, 34:1345-1353.
19. Packard CJ, Shepherd J: Lipoprotein heterogeneity and apolipoprotein B metabolism. [Review] [137 refs]. Arterioscler Thromb Vasc Biol 1997, 17:3542-3556.
20. Lindgren F, Elliot H, Gofman J: The ultracentrifugal characterization and isolation of human blood lipids and lipoproteins with applications to the study of atherosclerosis. J Phys Colloid Chem 1951, 55:80-87.
21. Krauss RM: Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. [Review] [29 refs]. Am Heart J 1987, 113:578-582.
22. Stampfer MJ, Krauss RM, Ma J, et al.: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276:882-888.
23. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276:875-881.
24. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
25. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. [Review] [98 refs]. Current Opinion in Lipidology 1994, 5:339-349.
26. Zambon A, Hokanson JE, Brown BG, Brunzell JD: Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999, 99:1959-1964.
27. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
28. Griffin BA, Freeman DJ, Tait GW, et al.: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994, 106:241-253.
29. Lahdenpera S, Syvanne M, Kahri J, Taskinen MR: Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 1996, 39:453-461.
30. Meyer BJ, Caslake MJ, McConnell MM, Packard CJ: Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels. Atherosclerosis 2000, 153:355-362.
31. Miller BD, Alderman EL, Haskell WL, et al.: Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996, 94:2146-2153.
32. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37-45.
33. Superko HR: What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials? [Review] [42 refs]. Curr Opin Lipidol 1996, 7:363-368.
34. Blankenhorn DH, Azen SP, Kramsch DM, et al.: Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993, 119:969-976.
35. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts [published erratum appears in JAMA 1988, 259:2698]. JAMA 1987, 257:3233-3240.
36. Jukema JW, Bruschke AV, van Boven AJ, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Dection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
38. Otto C, Richter WO, Schwandt P: Contribution of fibrinogen and lipoproteins to plasma viscosity in hypercholesterolemia and hypertriglyceridemia: evaluation by selective depletion of low-density lipoproteins or fibrinogen. Metab Clin Exp 2000, 49:810-813.
39. Saigo M, Abe S, Ogawa M, et al.: Plasma level of triglyceriderich lipoprotein remnants is closely associated with the activation of coagulation factor VII in patients with myocardial infarction. Thromb Res 2000, 100:9-17.
40. Gianturco SH, Bradley WA, Gotto AM, Jr., et al.: Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. J Clin Invest 1982, 70:168-178.
41. Wilson MA, Vega GL, Gylling H, Grundy SM: Persistence of abnormalities in metabolism of apolipoproteins B-100 and A-I after weight reduction in patients with primary hypertriglyceridemia. Arterioscler Thromb 1992, 12:976-984.
42. Chiba T, Miura S, Sawamura F, et al.: Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Arterioscler Thromb Vasc Biol 1997, 17:2601-2608.
43. Excoffon KJ, Liu G, Miao L, et al.: Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol 1997, 17:2532-2539.
44. Clee SM, Bissada N, Miao F, et al.: Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res 2000, 41:521-531.
45. Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. [Review] [9 refs]. Am J Cardiol 1998, 81:66B-69B.
46. Superko HR, Krauss RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992, 95:69-76.
47. Kashyap M, Evans R, Simmons P, et al.: New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. J Am Coll Cardiol 2000, 35:326A.
48. Freeman DJ, Packard CJ, Shepherd J, Gaffney D: Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high-density lipoprotein cholesterol and transfer protein activity. Clin Sci (Colch 1990, 79:575-581.
49. Caslake MJ, Packard CJ, Gaw A, et al.: Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993, 13:702-711.
50. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
51. The Bezafibrate Infarction Prevention (BIP) Study: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. [In Process Citation]. Circulation 2000, 102:21-27.
52. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
53. Gordon T, Castelli WP, Hjortland MC, et al.: High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977, 62:707-714.
54. Patterson B, Satyanarayana R, Elias N, Klein S: Effect of glucose on VLDL triglyceride metabolism: cross-validation of novel stable isotope. Circulation 1999, 100:I470.
55. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
56. Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
57. Ericsson CG, Hamsten A, Nilsson J, et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853.
58. Frick MH, Syvanne M, Nieminen MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96:2137-2143.
59. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progession of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
60. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
61. Watts GF, Mandalia S, Brunt JN, et al.: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461-1467.
62. Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996, 16:697-704.
63. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.